# Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone

Study · id `cardio:ct-nct01257412` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01257412](<https://clinicaltrials.gov/study/NCT01257412>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01257412

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 375 participants.

## Technical summary

Registry record NCT01257412. Randomized; quadruple masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2013-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 375 participants (planned count; ClinicalTrials.gov record NCT01257412, source copy `cardio:ctgov-nct01257412-2012-03-01`, retrieved 2026-10-26)
- Start date: 2012-01 (registry gives no type) (ClinicalTrials.gov record NCT01257412, source copy `cardio:ctgov-nct01257412-2012-03-01`, retrieved 2026-10-26)
- Primary completion: 2013-06 (anticipated) (ClinicalTrials.gov record NCT01257412, source copy `cardio:ctgov-nct01257412-2012-03-01`, retrieved 2026-10-26)
- Completion: 2013-06 (anticipated) (ClinicalTrials.gov record NCT01257412, source copy `cardio:ctgov-nct01257412-2012-03-01`, retrieved 2026-10-26)
- Countries: India (ClinicalTrials.gov record NCT01257412, source copy `cardio:ctgov-nct01257412-2012-03-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "SUSPENDED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01257412-2012-03-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone
- Condition: Type 2 Diabetes
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY
- Collaborator: Bristol-Myers Squibb
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)

## Provenance

Content hash: fb70f9159b4881e3fae3ff83bda9ba3449578d6179dead8d5fa88184d8bc13b4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
